These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24769756)

  • 1. Metastasis: understanding the prowess of mutant p53.
    McCarthy N
    Nat Rev Cancer; 2014 Jun; 14(6):385. PubMed ID: 24769756
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.
    Weissmueller S; Manchado E; Saborowski M; Morris JP; Wagenblast E; Davis CA; Moon SH; Pfister NT; Tschaharganeh DF; Kitzing T; Aust D; Markert EK; Wu J; Grimmond SM; Pilarsky C; Prives C; Biankin AV; Lowe SW
    Cell; 2014 Apr; 157(2):382-394. PubMed ID: 24725405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Shinchi H; Natsugoe S
    World J Surg; 2016 Aug; 40(8):1977-84. PubMed ID: 26940582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functions of TAp63 and p53 in restraining the development of metastatic cancer.
    Tan EH; Morton JP; Timpson P; Tucci P; Melino G; Flores ER; Sansom OJ; Vousden KH; Muller PA
    Oncogene; 2014 Jun; 33(25):3325-33. PubMed ID: 23873029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
    Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
    Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
    Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
    Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of p53 gene mutations in the supernatant of pancreatic juice and plasma from patients with pancreatic carcinomas.
    Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Motoo Y; Sawabu N
    Pancreas; 2004 Jan; 28(1):13-9. PubMed ID: 14707724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.
    Zhou R; Shanas R; Nelson MA; Bhattacharyya A; Shi J
    Int J Cancer; 2010 Jan; 126(2):395-404. PubMed ID: 19609950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
    Yan W; Liu G; Scoumanne A; Chen X
    Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
    Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
    Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
    Xia W; Bai H; Deng Y; Yang Y
    J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.
    Zhong Y; Macgregor-Das A; Saunders T; Whittle MC; Makohon-Moore A; Kohutek ZA; Poling J; Herbst BT; Javier BM; Cope L; Leach SD; Hingorani SR; Iacobuzio-Donahue CA
    Clin Cancer Res; 2017 Mar; 23(6):1607-1620. PubMed ID: 27637888
    [No Abstract]   [Full Text] [Related]  

  • 13. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy, p53, and pancreatic cancer.
    Iacobuzio-Donahue CA; Herman JM
    N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer.
    Batchu RB; Gruzdyn OV; Qazi AM; Kaur J; Mahmud EM; Weaver DW; Gruber SA
    Surgery; 2015 Oct; 158(4):981-6; discussion 986-7. PubMed ID: 26189069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
    Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
    Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
    Loukopoulos P; Kanetaka K; Takamura M; Shibata T; Sakamoto M; Hirohashi S
    Pancreas; 2004 Oct; 29(3):193-203. PubMed ID: 15367885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer.
    Chang Q; Jurisica I; Do T; Hedley DW
    Cancer Res; 2011 Apr; 71(8):3110-20. PubMed ID: 21343390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction.
    Butz J; Wickstrom E; Edwards J
    BMC Biotechnol; 2003 Jul; 3():11. PubMed ID: 12877750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.